Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Arcutis Biotherapeutics, Inc.

Get SEC filing alerts via email and in your feed for Arcutis Biotherapeutics, Inc.

ARQT

Arcutis Biotherapeutics, Inc.

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in developing and marketing innovative topical and systemic treatments for immune-mediated dermatological diseases. Its core products include ZORYVE, a portfolio of PDE4 inhibitor creams and foams approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis targets dermatologists, primary care providers, and pediatricians, leveraging proprietary formulations and a focused development platform to address unmet needs in chronic skin conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Arcutis Biotherapeutics, Inc.

1
1
Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics Reports 60% Revenue Growth to $105.4 Million in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics Reports Fiscal Year 2025 Results with 123% Revenue Growth

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics Reports 122% Revenue Growth to $99.2 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics Reports 164% Revenue Growth to $81.5 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics Reports 33% Revenue Growth to $65.8 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics Reports 17% Revenue Growth, 452% Increase in Product Revenue in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments